Genmab is going through a growth spurt and expands on three continents

Genmab keeps expanding its workforce in Europe, the US and Japan to prepare for handling drug commercialization on its own.

Genmab CEO Jan van de Winkel | Photo: Stine Bidstrup/ERH

If Genmab's drug tisotumab vedotin is approved in the US in October as expected, the firm will take on its own sales and marketing for the first time.

The Danish biotech company is currently expanding its workforce to prepare for participating in commercial activities with US company Seagen, formerly Seattle Genetics, with which it shares the rights for tisotumab vedotin equally.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

CHMP to remove 100 generic medicines from market

Due to fraudulent clinical trials from a contract research organization, the EMA’s expert committee, the CHMP, is now suspending marketing approval authorizations for around 100 generic drugs on the market.

Further reading

Related articles

Latest news

See all jobs